Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 8 (1), 9045

Efficacy of Two Different Dosages of Levofloxacin in Curing Helicobacter Pylori Infection: A Prospective, Single-Center, Randomized Clinical Trial

Randomized Controlled Trial

Efficacy of Two Different Dosages of Levofloxacin in Curing Helicobacter Pylori Infection: A Prospective, Single-Center, Randomized Clinical Trial

Huo-Ye Gan et al. Sci Rep.


Bismuth + proton pump inhibitor (PPI) + amoxicillin + levofloxacin is one of the bismuth quadruple therapy regimens widely used for the eradication of H. pylori infection. The recommended dosage of levofloxacin is 500 mg once daily or 200 mg twice daily to eradicate H. pylori infection. The aim of the present open-label, randomized control trial was to compare the effectiveness, safety, and compliance of different dosages of levofloxacin used to cure Helicobacter pylori infection. Eligible patients were randomly assigned to receive esomeprazole, amoxicillin, colloidal bismuth pectin and levofloxacin 500 mg once/day (group A) or levofloxacin 200 mg twice/day (group B) for 14 days. The primary outcome was the eradication rates in the intention-to-treat (ITT) and per protocol (PP) analyses. Overall, 400 patients were enrolled. The eradication rates in group A and group B were 77.5% and 79.5% respectively, in the ITT analysis, and 82.9% and 86.4%, respectively, in the PP analysis. No significant differences were found between two groups in terms of eradication rate, adverse effects or compliance. Oral levofloxacin 200 mg twice daily was similar in efficacy for eradicating H. pylori infection to oral levofloxacin 500 mg once daily but with lower mean total costs.

Conflict of interest statement

The authors declare no competing interests.


Figure 1
Figure 1
The patients flowchart.

Similar articles

See all similar articles


    1. Su J, et al. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine (Baltimore) 2017;96(7):e5859. doi: 10.1097/MD.0000000000005859. - DOI - PMC - PubMed
    1. Aktaş B, et al. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies. Eur J Gastroenterol Hepatol. 2015;27(7):769–75. doi: 10.1097/MEG.0000000000000372. - DOI - PubMed
    1. Paoluzi OA, et al. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World J Gastroenterol. 2015;21(21):6698–705. doi: 10.3748/wjg.v21.i21.6698. - DOI - PMC - PubMed
    1. Fallone CA, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51–69. doi: 10.1053/j.gastro.2016.04.006. - DOI - PubMed
    1. Tan B, et al. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PLoS One. 2017;12(4):e0175625. doi: 10.1371/journal.pone.0175625. - DOI - PMC - PubMed

Publication types

MeSH terms